Revvity, Inc. (RVTY) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $93.51. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of RVTY = $66.26 (-29.1% from the current price, the stock appears overvalued). Analyst consensus target is RVTY = $115 (+23.1% upside).
Valuation: RVTY trades at a trailing Price-to-Earnings (P/E) of 41.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.84.
Financials: revenue is $2.9B, -4.4%/yr average growth. Net income is $242M, growing at -16.6%/yr. Net profit margin is 8.5% (thin). Gross margin is 53.1% (-7 pp trend).
Balance sheet: total debt is $3.5B against $7.3B equity (Debt-to-Equity (D/E) ratio 0.48, conservative). Current ratio is 1.68 (strong liquidity). Debt-to-assets is 28.9%. Total assets: $12.2B.
Analyst outlook: 17 / 29 analysts rate RVTY as buy (59%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 27/100 (Fail), Growth 15/100 (Fail), Past 100/100 (Pass), Health 83/100 (Pass), Moat 65/100 (Partial), Future 58/100 (Partial), Income 45/100 (Partial).
